After adjusting for covariates like patient age and oral steroid cumulative dose, tumor necrosis factor-alpha inhibitors do not reduce hypertension risk among patients diagnosed with rheumatoid arthritis (RA), according to findings reported at the 2015 ACR/ARHP Annual Meeting.
SAN FRANCISCO, CA—Introducing one or more sequential biologic agents increases the rate of adverse events and infection when compared to treatment with methotrexate alone in children with juvenile idiopathic arthritis (JIA),research presented at the 2015 ACR/ARHP Annual Meeting has found.
Disease severity and disability scores are significantly higher among women than men at initiation of ankylosing spondylitis (AS) treatment with tumor necrosis factor (TNF) blockers, according to a study reported at the 2015 ACR/ARHP Annual Meeting.
Ofatumumab is safe and effective against rheumatoid arthritis (RA), a systematic review and meta-analysis of data from three trials presented at the 2015 ACR/ARHP Annual Meeting has confirmed.
Patients with rheumatoid arthritis (RA) who were inadequate responders or intolerant of anti-TNF therapy had significant and clinically meaningful outcomes with sarilumab at doses of 150mg or 200mg every 2 weeks plus a DMARD, reported Vibeke Strand, MD, from Stanford University Medical Center, Palo Alto, CA, at the 2015 ACR/ARHP Annual Meeting.
There were no major differences in efficacy, clinical outcomes, and time to response among adalimumab, abatacept, etanercept, and infliximab in the treatment of rheumatoid arthritis (RA), reported Yusuf Yazici, MD, from New York School of Medicine, Department of Medicine, Division of Rheumatology, New York, NY, at the 2015 ACR/ARHP Annual Meeting.
Higher levels of sodium intake are associated with a lower risk of hip fractures among postmenopausal women, but adherence to sodium-intake recommendations for cardiovascular health does not affect bone mineral density (BMD), according to findings from the Women’s Health Initiative (WHI) reported at the 2015 ACR/ARHP Annual Meeting.
Treatment with Prolia (denosumab) or bisphosphonates was associated with a low incidence rate of potential osteonecrosis of the jaw among postmenopausal women with osteoporosis, according to data presented by Fei Xue, MD, Center for Observational Research, Amgen Inc, at the 2015 ACR/ARHP Annual Meeting.
Treatment with hyaluronic acid (HA) for elderly patients with knee osteoarthritis (OA) is associated with significantly longer delay to knee arthroplasty (KA), according to Roy D. Altman, MD, Professor of Medicine at the David Geffen School of Medicine at UCLA, Los Angeles, CA, at the 2015 ACR/ARHP Annual Meeting.
Long-term etanercept is associated with modestly better treatment retention rates than adalimumab among patients with rheumatoid arthritis (RA), according to an analysis of data from the RHUMADATA® clinical registry and database presented at the 2015 ACR/ARHP Annual Meeting.
Please login or register first to view this content.
